Food and Drug Administration, HHS.
The Food and Drug Administration (FDA or Agency) has determined that it is necessary for manufacturers of certain reusable medical devices to include in their premarket notifications (510(k)s) instructions for use which have been validated and validation data regarding cleaning, disinfection, and sterilization, for which a substantial equivalence determination may be based. This notice includes a list of these reusable devices that will require validated instructions for use and validation data in their premarket notification. FDA is publishing this list in accordance with the requirements established by the 21st Century Cures Act. This action ensures that the premarket requirements for these device types are clear and predictable which facilitates more efficient review of these 510(k)s.
These actions are effective on August 8, 2017.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Constance Soves, Food and Drug Administration, Center for Devices and Radiological Health, 10903 New Hampshire Ave., Bldg. 66, Rm. 1437, Silver Spring, MD 20993-0002, 301-796-6951.
End Further Info
Start Supplemental Information
The Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 301 et seq.), as amended, established a comprehensive system for the regulation of medical devices intended for human use. Section 513 of the FD&C Act (21 U.S.C. 360c) establishes three categories (classes) of devices, based on the regulatory controls needed to provide reasonable assurance of their safety and effectiveness. The three categories of devices are class I (general controls), class II (special controls), and class III (premarket approval).
Devices introduced into interstate commerce for the first time on or after May 28, 1976 (generally referred to as post-amendments devices), are classified automatically by statute (section 513(f) of the FD&C Act) into class III without any FDA rulemaking process. These devices remain in class III and require premarket approval, unless FDA initiates one of the following procedures: (1) FDA reclassifies the device into class I or II; (2) FDA issues an order classifying the device into class I or II in accordance with section 513(f)(2) of the FD&C Act; or (3) FDA issues an order finding the device to be substantially equivalent, under section 513(i), to a predicate device that is already legally marketed. The Agency determines whether new devices are substantially equivalent to predicate devices through review of premarket notifications under section 510(k) of the FD&C Act (21 U.S.C. 360(k)). Section 510(k) of the FD&C Act and its implementing regulations, codified in Title 21 of the Code of Federal Regulations (21 CFR part 807, subpart E), require persons who intend to market a new device that does not require a premarket approval application under section 515 of the FD&C Act (21 U.S.C. 360e) to submit a premarket notification report (510(k)) containing information that allows FDA to determine whether the new device is “substantially equivalent” within the meaning of section 513(i) of the FD&C Act to a legally marketed device that does not require premarket approval.
On December 13, 2016, the President signed into law the 21st Century Cures Act (Pub. L. 114-255) (Ref. 1). Section 3059 of the 21st Century Cures Act, in part, amends section 510 of the FD&C Act to require FDA to publish in the Federal Register a notice identifying a list of reusable device types that must include validated instructions for use and validation data regarding cleaning, disinfection, and sterilization in their 510(k) submissions. This section also Start Printed Page 26808provides that a 510(k) submission for a reusable device may not be substantially equivalent to a predicate device if the validated instructions for use and reprocessing validation data submitted as part of the 510(k) are inadequate.
Manufacturers of reusable medical devices are responsible for having labeling that bears adequate directions for use, including instructions on preparing a device for use under 21 CFR 801.5 and 801.109. However, in recent years, there have been significant changes in knowledge and technology involved in reprocessing reusable medical devices. Additionally, there has been an evolution towards more complex reusable medical device designs that are more difficult to clean, disinfect, and sterilize. FDA believes reusable devices must be designed for adequate reprocessing and safe reuse, with comprehensive and clear instructions for effective reprocessing procedures for use by health care facilities that reprocess these devices.
II. Requirements for Validated Reprocessing Instructions and Reprocessing Validation Data for Reusable Medical Devices
A reusable medical device is one intended for repeated use either on the same or different patients, with appropriate cleaning and other reprocessing steps between uses. FDA has issued recommendations for reprocessing reusable devices in relevant documents, including the FDA guidance “Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling,” as information on the reprocessing validation methods necessary to be reported in a 510(k) submission (Ref. 2). FDA expects specific required validation data regarding cleaning, disinfection, and sterilization to be included in 510(k) submissions for certain reusable medical device types as outlined in tables 1 and 2 below.
FDA believes that a majority of manufacturers for the reusable devices listed below are already conducting validation of their reprocessing instructions because FDA already has provided recommendations for reprocessing validation in relevant FDA documents. Sponsors of new 510(k) notifications for reusable devices identified in the tables below must also include validation data regarding cleaning, disinfection, and sterilization, in addition to all the other required elements of a 510(k) identified in 21 CFR 807.87, starting on August 8, 2017.
III. List of Certain Reusable Medical Devices and Design Features
The 21st Century Cures Act (section 3059) requires the Agency to identify and publish a list of reusable device types that are required to include “instructions for use” and “validation data” regarding cleaning, disinfection, and sterilization in 510(k) notifications. Accordingly, FDA is publishing the list in table 1 that identifies those reusable medical devices that FDA has determined pose a greater likelihood of microbial transmission and represent a high risk of infection (subclinical or clinical) if they are not adequately reprocessed.
FDA believes arthroscopes, laparoscopic instruments, and electrosurgical instruments, and their respective accessories with specific design features, identified in table 2, may pose a challenge to adequate reprocessing. 510(k) notifications for such devices that incorporate any of the design features listed in table 2 must include validated reprocessing instructions and reprocessing validation data reports, and if such are determined to be inadequate, FDA will find the device not substantially equivalent.
Table 1—Reusable Devices That Require Validation Data and Validated Reprocessing Instructions Be Included in 510(k) Notification and Upon Which FDA Will Determine Substantial Equivalence
|Device type||Product code||Device name||21 CFR section|
|Bronchoscopes (flexible or rigid) and accessories||EOQ PSV||Bronchoscope (flexible or rigid) Ultrasound bronchoscope||21 CFR 874.4680 21 CFR 892.1550|
| ||KTI||Bronchoscope accessory||21 CFR 874.4680|
| ||BTG||Brush, biopsy, bronchoscope (non-rigid)||21 CFR 874.4680|
| ||JEI||Claw, foreign body, bronchoscope (non-rigid)||21 CFR 874.4680|
| ||JEL||Curette, biopsy, bronchoscope (rigid)||21 CFR 874.4680|
| ||BST||Curette, biopsy, bronchoscope (non-rigid)||21 CFR 874.4680|
| ||BWH||Forceps, biopsy, bronchoscope (non-rigid)||21 CFR 874.4680|
| ||JEK||Forceps, biopsy, bronchoscope (rigid)||21 CFR 874.4680|
| ||ENZ||Telescope, laryngeal-bronchial||21 CFR 874.4680|
| ||KTR||Tube, aspirating, bronchoscope (rigid)||21 CFR 874.4680|
| ||JEJ||Tubing, Instrumentation, bronchoscope (brush sheath A/O aspirating)||21 CFR 874.4680|
|Ear, Nose, and Throat (ENT) endoscopes and accessories||EOX GCL||Esophagoscope (flexible or rigid) Esophagoscope, general & plastic surgery||21 CFR 874.4710 21 CFR 876.1500|
| ||FDW||Esophagoscope, rigid, gastro-urology||21 CFR 876.1500|
| ||EOB||Nasopharyngoscope (flexible or rigid)||21 CFR 874.4760|
| ||EQN||Laryngoscope, nasopharyngoscope||21 CFR 874.4760|
| ||EWY||Mediastinoscope, surgical, and accessories||21 CFR 874.4720|
|Gastroenterology and Urology Endoscopes that have elevator channels (not including accessories) [e.g., duodenoscopes used for endoscopic retrograde cholangiopancreatography (ERCP)]||FDT FAK
ODF||Duodenoscope and accessories, flexible/rigid Panendoscope (gastroduodenoscope)
Mini endoscope, gastroenterology-urology||21 CFR 876.1500 21 CFR 876.1500
21 CFR 876.1500|
|Automated Reprocessors for Reusable Devices||FEB NZA||Accessories, cleaning, for endoscopes Accessories, germicide, cleaning, for endoscopes||21 CFR 876.1500 21 CFR 876.1500|
| ||OUJ||High level disinfection reprocessing instrument for ultrasonic transducers, mist||21 CFR 892.1570|
| ||NVE||Washer, cleaner, automated, endoscope||21 CFR 876.1500|
| ||PSW||High level disinfection reprocessing instrument for ultrasonic transducers, liquid||21 CFR 892.1570|
|Start Printed Page 26809|
|Other Flexible Gastroenterology and Urology Endoscopes 1 (not including accessories)||FDF FBN||Colonoscope and accessories, flexible/rigid Choledochoscope and accessories, flexible/rigid||21 CFR 876.1500 21 CFR 876.1500|
| ||FDA||Enteroscope and accessories||21 CFR 876.1500|
| ||FDS||Gastroscope and accessories, flexible/rigid||21 CFR 876.1500|
| ||FAJ||Cystoscope and accessories, flexible/rigid||21 CFR 876.1500|
| ||FGB||Ureteroscope and accessories, flexible/rigid||21 CFR 876.1500|
| ||ODG||Endoscopic ultrasound system, gastroenterology-urology||21 CFR 876.1500|
|Neurological endoscopes (not including accessories)||GWG||Endoscope, neurological||21 CFR 882.1480|
|Water-based heater-cooler systems for use in operating rooms||DWC DWJ||Controller, Temperature, Cardiopulmonary Bypass System, Thermal Regulating||21 CFR 870.4250 21 CFR 870.5900|
|System, Surgical, Computer Controlled Instrument||NAY||System, Surgical, Computer Controlled Instrument||21 CFR 876.1500|
|Arthroscopes and accessories 2||HRX||Arthroscope||21 CFR 888.1100|
|Laparoscopic instruments and accessories 2||GCJ||Laparoscope, general and plastic surgery||21 CFR 876.1500|
|Electrosurgical instruments and accessories 2||GEI||Electrosurgical, cutting and coagulation and accessories||21 CFR 878.4400|
|1 For endoscopes that fall under these product codes, 510(k) submissions must include reprocessing validation data for those endoscopes which are flexible.|
|2 For devices that fall under these product codes, 510(k) submissions must include reprocessing validation data if the device possesses any of the design features listed in table 2 below.|
Table 2—Design Features Which May Pose a Challenge to Adequate Reprocessing for Arthroscopes, Laparoscopic Instruments, and Electrosurgical Instruments, and Their Respective Accessories
|Lumens (especially lumens of flexible design, multiple internal lumens, lumens that are not freely accessible, bifurcated lumens, lumens with internal surfaces that are not smooth, have internal ridges or sharp angles, or are too small to permit a brush to pass through).|
|Hinges, depressions, joints with gaps, overlapping or butted joints that result in acute angles, or ribbed or otherwise “roughened” surfaces (e.g., jaws).|
|Interior device channels.|
|Sleeves surrounding rods, blades, activators, inserters, etc.|
|Shafts within lumens.|
|Adjacent device surfaces between which debris can be forced or caught during use.|
|Fittings with very close tolerances.|
|Clamps that cannot be fully opened for cleaning.|
|Small internal parts (e.g., springs, magnets, etc.) that may become soiled.|
|Ridges, articulations or grooves.|
|Rough, irregular, discontinuous surfaces that can entrap or retain soil.|
|Porous materials (smooth surfaces are desirable, where possible).|
|Junctions between insulating sheaths and activating mechanisms (as in certain laparoscopic instruments).|
|Internal movable device components such as multiple cables.|
|Device features that may entrap debris that can later become aerosolized (e.g., through application of power, etc.).|
|Devices with these or other design features that cannot be disassembled for reprocessing.|
The Agency believes that these devices currently have the greatest risk of infection transmission and inadequate performance if not adequately reprocessed. In the future, the Agency may reevaluate and revise both tables as it deems necessary.
IV. Paperwork Reduction Act of 1995
This notice refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collections of information in part 801 have been approved under OMB control number 0910-0485 (medical device labeling); the collections of information in part 807, subpart E have been approved under OMB control number 0910-0120 (premarket notification); and the collections of information in 21 CFR part 820 have been approved under OMB control number 0910-0073 (quality system regulation).
The following references are on display in the Division of Dockets Management (see ADDRESSES) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at https://www.regulations.gov. FDA has verified the Web site addresses, as of the date this document publishes in the Federal Register, but Web sites are subject to change over time.
1. 21st Century Cures Act, Public Law 114-255, available at https://www.congress.gov/114/bills/hr34/BILLS-114hr34eah.pdf.
2. FDA's Guidance, Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling, March 2015, available at http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm253010.pdf.
Start Printed Page 26810
End Supplemental Information
Dated: June 5, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-12007 Filed 6-8-17; 8:45 am]
BILLING CODE 4164-01-P